embecta reduces Viva™ insulin pen needle pricing to £2 per box across all needle lengths
Through the NHS Drug Tariff Review process, embecta has agreed a reduction in the price of its Viva™ insulin pen needles, with all needle lengths soon to be available to the NHS at just £2.00 per box. embecta Micro-Fine™ insulin pen needles have also been accepted for a price reduction to £2.90 per box.
This new pricing supports NHS organisations in delivering high-quality diabetes care while achieving greater value for money, without compromising on quality, reliability or patient support.
While confirmation of the go-live date is still awaited, this marks an exciting milestone that will provide the NHS with greater choice, improved affordability and continued access to trusted injection solutions.
Available in a full range of 4mm, 5mm, 6mm and 8mm needle lengths, Viva™ pen needles are compatible with widely used pen injection devices, providing flexibility to meet the individual needs of people living with diabetes.
Manufactured to stringent ISO quality standards and rigorously tested to ensure consistent performance, Viva™ pen needles offer healthcare professionals confidence in the products they recommend.
The announcement comes at a time when NHS organisations continue to seek cost-effective solutions that maintain high standards of patient care. However, embecta believes the new pricing is only part of the story.
A key differentiator is embecta’s commitment to continuity of supply. embecta operates a well-established global manufacturing and supply network, with Viva™ pen needles produced within its own manufacturing facilities – providing NHS organisations with confidence in the long-term availability of products.
Beyond the product itself, embecta also offers comprehensive implementation support to help organisations transition to Viva™ pen needles. This includes the provision of product samples to support evaluation and formulary decisions, alongside education for both healthcare professionals and people living with diabetes. By supporting both clinicians and people living with diabetes throughout the transition process, embecta aims to help maximise the benefits of any formulary change while maintaining positive experiences.
Viva™ pen needles also benefit from the experience of embecta’s global diabetes heritage. embecta pen needles are the number one selling brand of pen needles worldwide, trusted by more than 30 million people globally. The needles are intended for single use only, helping to support safe injection practice and maintain sterility with every injection.
For more information about Viva™ insulin pen needles and embecta’s diabetes care portfolio, visit https://www.embecta.com/gb/en-gb/.